Evolent Health (EVH) FY Conference June 03, 2025 02:20 PM ET Speaker0 Good afternoon, everyone. Let's go ahead and get started. Thanks for coming to the Evolent Health presentation. For those of you whom I've not yet met, my name is Ryan Daniels. I'm the HCIT and health care services analyst here that covers the company. I'm joined on the stage by Seth Blackley. Seth is one of the company's cofounders and the CEO. And John Johnson, the CFO, is in the front row. He'll be in the breakout session as well, whic ...

Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this health care software and consulting services provider would post a loss of $0.02 per share when it actually produced a loss of $0.02, delivering no surprise.Over the ...

Evolent Health (EVH) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Seth Blackley - Co-Founder, CEO & DirectorJohn Johnson - Chief Financial OfficerRyan Daniels - Group Head–Healthcare Technology and ServicesJeff Garro - Managing DirectorKyle Aikman - AssociateMatthew Shea - Equity Research AssociateConstantine Davides - Managing DirectorCharles Rhyee - Managing DirectorDavid Larsen - Managing Director Conference Call Participants None - AnalystMatthew Gillmor - Director & Equity Resear ...

Evolent Health (EVH) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Welcome to the Evolent Earnings Conference Call for the First Quarter Ended 03/31/2025. As a reminder, this conference call is being recorded. Your hosts for the call today from Evolent are Seth Blackley, Chief Executive Officer and John Johnson, Chief Financial Officer. This call will be archived and available later this evening and for the next week via the webcast on the company's website in the section titled Investor Relations ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 | | | _________________________ Evolent Health, Inc. | | | | | | --- ...

Certain statements made in this report and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," ...

Exhibit 99.1 1 The rising medical costs impacting health plans continue to drive robust demand for Evolent's complex specialty care solutions. Evolent Announces First Quarter 2025 Results WASHINGTON (May 8, 2025) – Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, ...

WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, ...

The average comprises 15 short-term price targets ranging from a low of $12 to a high of $20, with a standard deviation of $2.72. While the lowest estimate indicates an increase of 15.9% from the current price level, the most optimistic estimate points to a 93.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Evolent Health (EVH) closed the last tr ...

Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts. WASHINGTON, April 22, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that a new director nominee will stand for election to the Board of Directors at the annual meeting of stockhold ...